Vaccine | Tumor type | Adverse events/potential autoimmunity | References |
---|---|---|---|
Fibroblast growth factor (FGF)-2 peptide | Murine pulmonary metastatic cancer | No effect on wound healing, reproduction, organogenesis in offspring | [61] |
Vascular endothelial growth factor receptor (VEGFR)-2 FLK1 DNA | Murine melanoma, colon carcinoma and lung carcinoma, metastatic pulmonary metastasis | No impairment of fertility, neuromuscular performance or hematopoiesis, slight delay in wound healing | [62] |
VEGFR2 polypeptides, Listeria monocytogenes vector, microbial adjuvant, listeriolysin-O | Murine HER2 + breast cancer | No effect on wound healing or fertility | [63] |
VEGF and Neisseria meningitidis outer membrane | Numerous in rats, rabbits, primates | No effect on skin deep wound healing | [64] |
Endoglin DNA, Salmonella typhimurium vector | Murine tumors | No effect on wound healing | [65] |
Survivin DNA Listeria monocytogenes vector | Murine pulmonary metastases of non-small cell lung carcinoma | No effect on wound healing or fertility | [66] |
Tumor endothelial marker (TEM)-1 DNA fused to domain of the C fragment of tetanus toxoid | Numerous murine models | No effect on wound healing or reproduction | [67] |
Notch ligand delta-like ligand 4 (DLL4) DNA | Murine mammary carcinoma | No effect on wound healing | [68] |
CIGB-247, VEGF variant with bacterial adjuvant | Phase I clinical study of patients with advanced solid tumors | Only grade 1–2 adverse events | [50] |
VEGFR2 peptide (VEGFR2-169) plus gemcitabine | Phase I clinical study of advanced pancreatic cancer | No severe adverse events, 83 % had immunological reaction at injection site | [51] |
CIMAvax® epidermal growth factor (EGF) | Human clinical study of patients undergoing surgery during treatment with CIMAvax® EGF | No wound dehiscence, wound infection, delayed wound healing, fistula formation, abscess formation or bleeding associated with surgery during treatment with CIMAvax® EGF occurred | [69] |